Stock Events

Stock Events

Royalty Pharma 

$40.8
352
-$0.88-2.11% Today

Statistics

Day High
41.72
Day Low
40.86
52W High
41.68
52W Low
30.85
Volume
3,377,221
Avg. Volume
4,210,067
Mkt Cap
14.93B
P/E Ratio
16.39
Dividend Yield
2.26%
Dividend
0.92

Upcoming

20
FEB
Dividend Ex
Increased
 
10
MAR
Dividend Payment
Increased
 
18
MAY
Dividend Ex
Estimated
 
10
JUN
Dividend Payment
Estimated
 
17
AUG
Dividend Ex
Estimated
 

Dividends

2.26%Dividend Yield
Dec 25
$0.22
Sep 25
$0.22
Jun 25
$0.22
Mar 25
$0.22
Dec 24
$0.21
10Y Growth
N/A
5Y Growth
6.69%
3Y Growth
5.52%
1Y Growth
6.82%

Earnings

11FebExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
0.75
0.93
1.11
1.29
Expected EPS
1.285099
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
0Revenue
1.72BNet Income

Analyst Ratings

$47.75Average Price Target
The highest estimate is 54.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RPRX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Royalty Pharma in the acquisition and management of pharmaceutical royalties, particularly through its string of acquisitions that expand its portfolio in similar therapeutic areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a large pharmaceutical company that competes with Royalty Pharma in the development and commercialization of medical treatments, and it also engages in deals and partnerships that involve royalty agreements.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the research, development, and commercialization of drugs in areas like HIV/AIDS, liver diseases, and oncology, competing with Royalty Pharma in acquiring royalties in these therapeutic areas.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in the pharmaceutical industry, focusing on acquiring and developing a portfolio of medicines, directly competing with Royalty Pharma in the market for drug royalties and investments in pharmaceutical innovations.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is a global healthcare company that competes with Royalty Pharma through its extensive drug development programs and partnerships that may involve royalty financing and agreements.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson is a diversified healthcare giant that competes across various segments, including pharmaceuticals. Its involvement in drug development and royalty agreements places it in competition with Royalty Pharma.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company, competing with Royalty Pharma in the acquisition of drug royalties and through its focus on innovative drug development.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is a global healthcare leader that competes with Royalty Pharma in the pharmaceutical sector, particularly through its efforts to secure drug royalties and its focus on innovative treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that competes with Royalty Pharma through its significant investments in drug development and its strategy to acquire and manage drug royalties.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing with Royalty Pharma in the market for pharmaceutical royalties, especially in the generic sector where royalties are a key component of profitability.

About

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Show more...
CEO
Mr. Pablo Gerardo Legorreta
Employees
75
Country
GB
ISIN
GB00BMVP7Y09

Listings

MX
MX
RPRXN.MX
XNAS
US
RPRX
F
DE
RPD.F
BOATS
BOATS
RPRX.BOATS

0 Comments

Share your thoughts

FAQ

What is Royalty Pharma stock price today?▼
The current price of RPRX is $40.8 USD — it has decreased by -2.11% in the past 24 hours. Watch Royalty Pharma stock price performance more closely on the chart.
What is Royalty Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Royalty Pharma stocks are traded under the ticker RPRX.
Is Royalty Pharma stock price growing?▼
RPRX stock has risen by +2.25% compared to the previous week, the month change is a +6.59% rise, over the last year Royalty Pharma has showed a +31.16% increase.
What is Royalty Pharma market cap?▼
Today Royalty Pharma has the market capitalization of 14.93B
When is the next Royalty Pharma earnings date?▼
Royalty Pharma is going to release the next earnings report on February 11, 2026.
What were Royalty Pharma earnings last quarter?▼
RPRX earnings for the last quarter are 1.17 USD per share, whereas the estimation was 0.99 USD resulting in a +18.08% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Royalty Pharma revenue for the last year?▼
Royalty Pharma revenue for the last year amounts to 0 USD.
What is Royalty Pharma net income for the last year?▼
RPRX net income for the last year is 1.72B USD.
Does Royalty Pharma pay dividends?▼
Yes, RPRX dividends are paid quarterly. The last dividend per share was 0.22 USD. As of today, Dividend Yield (FWD)% is 2.26%.
How many employees does Royalty Pharma have?▼
As of February 02, 2026, the company has 75 employees.
In which sector is Royalty Pharma located?▼
Royalty Pharma operates in the Health Care sector.
When did Royalty Pharma complete a stock split?▼
The last stock split for Royalty Pharma was on October 15, 2010 with a ratio of 1:4.
Where is Royalty Pharma headquartered?▼
Royalty Pharma is headquartered in New York, GB.